Primary Mitochondrial Myopathy (PMM) Rare diseases are one of the most challenging specialties within clinical trials, due to limited patient populations, lack of historic large scale studies to draw knowledge/clinician expertise and build upon, and frequently, lack of necessary funding to conduct thorough and multi-phased research. That is why Eurofins Central Laboratory is delighted to … [Read more...] about Primary Mitochondrial Myopathy (PMM)
Blog
Osteomyelitis Clinical Trials
Eurofins Central Laboratory is pleased to collaborate with The Emmes Company in the conduct of Diabetic Foot Osteomyelitis (DFO) clinical trials. … [Read more...] about Osteomyelitis Clinical Trials
CRO Emmes signs new five-year service agreement with Eurofins Central Laboratory
Emmes, a leading global full-service clinical research organization (CRO), together with its rare disease CRO Orphan Reach, today announced it has signed a new five-year service agreement to extend its current relationship with Eurofins Central Laboratory. Emmes is dedicated to helping private sector, government, non-profit and academic partners achieve their biopharmaceutical development and … [Read more...] about CRO Emmes signs new five-year service agreement with Eurofins Central Laboratory
Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients
Provides significantly higher positive predictive value (PPV) and negative predictive value (NPV) than any other kidney rejection assays (or tests) on the market. Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to introduce OmniGraf™, which combines the TruGraf® blood gene expression test … [Read more...] about Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients
Eurofins and Rite Aid launch an over-the-counter, FDA-authorized, at-home COVID-19 PCR test in all Rite Aid locations in the U.S.
Eurofins, through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit. The co-branded kits, available at all Rite Aid stores across 17 states in the USA, will offer customers a convenient way to test for the virus from their home and will detect the virus in symptomatic and asymptomatic patients. The at-home … [Read more...] about Eurofins and Rite Aid launch an over-the-counter, FDA-authorized, at-home COVID-19 PCR test in all Rite Aid locations in the U.S.
TruGraf contracted with Humana for in-network coverage of Medicare kidney transplant patients
Eurofins Transplant Genomics, Inc. (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is excited to announce the first national in-network contract for TruGraf, its proprietary gene expression test for subclinical acute rejection. Humana, a leading health care company that offers a wide range of insurance products and health and … [Read more...] about TruGraf contracted with Humana for in-network coverage of Medicare kidney transplant patients
Eurofins opens Europe-wide COVID-19 testing center network to facilitate summer travel
Easy, reliable, high-quality, and cost-effective testing for SARS-CoV-2 (COVID-19), in compliance with local regulatory requirements, is crucial to enabling millions of passengers to complete their journeys in comfort and safety. Eurofins has rapidly developed a broad network of around 500 testing centers across Europe and intends to have established around 1,000 testing centers by early … [Read more...] about Eurofins opens Europe-wide COVID-19 testing center network to facilitate summer travel
Eurofins launches a new multiplex PCR assay for rapid detection of the B.1.617 SARS-CoV-2 variant
Eurofins Technologies announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617, B.1.427/B.1.429, B.1.351 or P.1. The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 … [Read more...] about Eurofins launches a new multiplex PCR assay for rapid detection of the B.1.617 SARS-CoV-2 variant
Eurofins Expands its Global Sequencing Capabilities
Eurofins expands its global sequencing and mutation-specific PCR capabilities to detect COVID-19 Variants of Concern and of Interest As the number of types of COVID-19 Variants of Concern and of Interest increases, fast high throughput NGS sequencing is key to identify new variants while mutation specific PCR testing enables immediate detection and contact tracing. Eurofins continues to … [Read more...] about Eurofins Expands its Global Sequencing Capabilities
Eurofins expands its global sequencing and mutation-specific PCR capabilities to detect COVID-19 Variants of Concern and of Interest
As the number of types of COVID-19 Variants of Concern and of Interest increases, fast high throughput NGS sequencing is key to identify new variants while mutation specific PCR testing enables immediate detection and contact tracing. Eurofins continues to develop innovative COVID-19 testing solutions and has now reached two important milestones. Eurofins has sequenced more than 125,000 … [Read more...] about Eurofins expands its global sequencing and mutation-specific PCR capabilities to detect COVID-19 Variants of Concern and of Interest